---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-24-000006"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T11:11:01.336989+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health appoints Sandra Milligan as President effective April 1, 2024

## Summary
- Dr. Sandra Milligan appointed President, reporting to CEO Nicole Sandford, effective April 1, 2024.
- Base salary of $400,000; eligible for bonus up to 50% of base salary based on corporate goals.
- Granted stock option for 30,000 shares, vesting 25% per year over four years.
- Severance: 6 months salary and COBRA if terminated without cause after 12 months of employment.
- Over 25 years healthcare experience; previously EVP R&D at Organon, roles at Amgen, Genentech, Merck.

## SEC filing metadata
- accession: 0000926617-24-000006
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661724000006/0000926617-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661724000006/awh-20240316x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-24-000006
- JSON: https://secwatch.observer/filing/0000926617-24-000006.json
- Plain text: https://secwatch.observer/filing/0000926617-24-000006.txt

## Key facts
- Executive change
  Sandra Milligan was appointed as President at Aspira Women's Health Inc..
  - Action: appointed
  - Role: President
  source text: On March 16, 2024, Aspira Women’s Health Inc. (the “Company”) expanded its senior management team with the addition of Sandra Milligan, M.D., J.D. as President, effective as of April 1, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661724000006/0000926617-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.